Global Breast Cancer Liquid Biopsy Market, By Product (Consumables and Kits), Circulating Biomarkers (Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), ctRNA, Circulating Tumor Cells (CTCs), cfRNA, and Others), End Users (Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, and Pathology Laboratories) - Industry Trends and Forecast to 2030.
Breast Cancer Liquid Biopsy Market Analysis and Size
Liquid biopsy refers to a non-invasive medical procedure that involves the analysis of various biomarkers present in a sample of bodily fluids, typically blood, to detect and monitor various diseases, including cancer. It offers an alternative to traditional tissue biopsies, which require invasive procedures to obtain tissue samples. It is used to detect breast cancer, as it is more convenient for patients and is a less invasive method.
In a liquid biopsy, circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and other biomarkers are analyzed to provide valuable information about the presence of tumors, genetic mutations, treatment response, and disease progression. The procedure involves collecting a blood sample from the patient, isolating the desired components, and performing molecular analysis to examine the genetic material or proteins associated with the disease.
Data Bridge Market Research analyzes that the global breast cancer liquid biopsy market which was USD 278.07 million in 2022, would rocket up to USD 1,465.33 million by 2030, and is expected to undergo a CAGR of 23.09% during the forecast period.
The consumables segment dominates the product segment of the global breast cancer liquid biopsy market owing to the growing prevalence of breast cancer cases. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Breast Cancer Liquid Biopsy Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Year
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
By Product (Consumables and Kits), Circulating Biomarkers (Extracellular Vesicles (EVs), Cell-free DNA (cfDNA), ctRNA, Circulating Tumor Cells (CTCs), cfRNA, and Others), End Users (Laboratories, Hospitals, Physician Laboratories, Reference Laboratories, Public Health Laboratories, Research Institutes, Small Molecular Laboratories, and Pathology Laboratories)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa
|
|
Market Players Covered
|
F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (U.S.), Abbott (U.S.), Agilent Technologies Inc. (U.S.), Merck KGaA (U.S.), QIAGEN (Germany), Abcam plc. (U.K.), Cell Signaling Technology Inc. (U.S.), Koninklijke Philips N.V. (Netherlands), The Menarini Group (Italy), Genomic Health (U.S.), Johnson & Johnson Private Limited. (U.S.), Medtronic (Ireland), Siemens Healthineers (Germany), Biocept, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Fluxion Biosciences, Inc. (U.S.), FOUNDATION MEDICINE, INC. (U.S.), Sysmex Inostics Inc. (U.S.), ExoDx (U.S.), and Illumina, Inc. (U.S.) among others
|
|
Market Opportunities
|
|
Market Definition
Breast cancer liquid biopsy refers to the use of liquid biopsy techniques specifically for the detection and monitoring of breast cancer. It involves the analysis of biomarkers present in bodily fluids, typically blood, to gain insights into the presence of breast cancer, monitor disease progression, assess treatment response, and identify specific genetic mutations or alterations associated with the disease.
Global Breast Cancer Liquid Biopsy Market Dynamics
Drivers
- Rising prevalence of breast cancers
The growing prevalence of breast cancer in the current world is directly influencing the demand for specific diagnostics that offer more precision. Breast cancer liquid biopsy is a non-invasive, specialized, and precise diagnostics test emerging as a promising technique. This, in turn, has carved the way for market growth.
- Adoption of non-invasive diagnostic techniques
Breast cancer liquid biopsy offers a non-invasive alternative to traditional tissue biopsies which are invasive and can be associated with various risks and complications. Liquid biopsy provides a less burdensome and more patient-friendly approach to detecting and monitoring breast cancer, which is expected to drive market growth.
- Growing investment in healthcare facilities
Surging focus on improving the condition of healthcare facilities and improving the overall healthcare infrastructure is another important factor expected to drive market growth. The rising number of partnerships and strategic collaborations between the public and private players pertaining to funding and application of new and improved technology is further expected to drive market growth.
Opportunities
- Early detection and screening programs
There is an opportunity to implement widespread breast cancer liquid biopsy screening programs, particularly for high-risk populations. By detecting breast cancer at an early stage, these programs can significantly improve survival rates and patient outcomes. This is expected to create an opportunity for market growth.
-
Integration with the standard of care
Breast cancer liquid biopsy has the potential to become an integral part of the standard of care for breast cancer diagnostics and monitoring. Integrating liquid biopsy into routine clinical practice can provide healthcare professionals with valuable information for making treatment decisions and assessing treatment responses, which is expected to create an opportunity for market growth.
Restraints/Challenges
- Lack of skilled professionals
Performing breast cancer liquid biopsy requires specialized skills and expertise, particularly in areas such as histopathology, molecular pathology, and interpretation of results. The shortage of skilled pathologists, technicians, and molecular biologists can hinder the widespread adoption and efficient implementation of breast cancer liquid biopsy, leading to delays in diagnosis and treatment. This is expected to restrain market growth.
-
Stringent regulatory requirements
The global breast cancer liquid biopsy market is subject to strict regulatory oversight, ensuring patient safety, accuracy, and quality of diagnostic tests. Obtaining regulatory approvals and complying with regulations can be time-consuming and costly, particularly for new diagnostic technologies and companion diagnostics. Stringent regulatory requirements may slow down the pace of innovation and market entry for new products, which is expected to restrain market growth.
The global breast cancer liquid biopsy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyzes opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, and technological innovations in the market. To gain more info on the global breast cancer liquid biopsy market, contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In March 2023, REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker innovation, announced a new addition to its pipeline consisting of a novel biomarker approach in liquid biopsy for patients with advanced cancer. REVEAL GENOMICS machine learning-based technology applied to ctDNA was able to predict drug response and survival outcome in patients with metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitors
- In March 2021, Roche launched DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research
Global Breast Cancer Liquid Biopsy Market Scope
The global breast cancer liquid biopsy market is segmented into three notable segments based on product, circulating biomarkers, and end users. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product
- Consumables
- Kits
Circulating Biomarkers
- Extracellular Vesicles (EVs)
- Cell-free DNA (cfDNA)
- ctRNA
- Circulating Tumor Cells (CTCs)
- cfRNA
- Others
End Users
- Laboratories
- Hospitals
- Physician Laboratories
- Reference Laboratories
- Public Health Laboratories
- Research Institutes
- Small Molecular Laboratories
- Pathology Laboratories
Global Breast Cancer Liquid Biopsy Market Regional Analysis/Insights
The global breast cancer liquid biopsy market is analyzed and market size insights and trends are provided by country, product, circulating biomarkers, and end users as referenced above.
The countries covered in this market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.
North America is expected to dominate the global breast cancer liquid biopsy market due to the rising prevalence of breast cancer in the region. In addition, the growing investment in healthcare infrastructure is expected to drive market growth.
Asia-Pacific is expected to witness significant growth during the forecast period of 2023 to 2030 due to the adoption of non-invasive diagnostic techniques, increase in government initiatives to promote awareness, rise in medical tourism, growing research activities in the region, availability of massive untapped markets, large population pool, and the growing demand for quality healthcare in the region.
The country section of the report also provides individual market-impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as downstream and upstream value chain analysis, technical trends, Porter's five forces analysis, and case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, and the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed Base and New Technology Penetration
The global breast cancer liquid biopsy market also provides you with a detailed market analysis for every country's growth in healthcare expenditure for capital equipment, installed base of different kinds of products for the market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the market. The data is available for the historic period 2010-2020.
Competitive Landscape and Global Breast Cancer Liquid Biopsy Market Share Analysis
The global breast cancer liquid biopsy market competitive landscape provides details of competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major market players operating in the global breast cancer liquid biopsy market are:
- F. Hoffmann-La Roche Ltd (Switzerland)
- Thermo Fisher Scientific Inc.(U.S.)
- Abbott (U.S.)
- Agilent Technologies Inc. (U.S.)
- Merck KGaA (U.S.)
- QIAGEN (Germany)
- Abcam plc. (U.K.)
- Cell Signaling Technology Inc. (U.S.)
- Koninklijke Philips N.V. (Netherlands)
- The Menarini Group (Italy)
- Genomic Health (U.S.)
- Johnson & Johnson Private Limited. (U.S.)
- Medtronic (Ireland)
- Siemens Healthineers (Germany)
- Biocept, Inc. (U.S.)
- Bio-Rad Laboratories, Inc. (U.S.)
- Fluxion Biosciences, Inc. (U.S.)
- FOUNDATION MEDICINE, INC. (U.S.)
- Sysmex Inostics Inc. (U.S.)
- ExoDx (U.S.)
- Illumina, Inc. (U.S.)
SKU-